Keyur P. Patel, M.D., Ph.D., FCAP

Peer-Reviewed Articles

1. Lapelusa, M, Qiao, W, Iorgulescu, B, San Lucas, FA, Patel, KP, Bhamidipati, D, Thomas, J, You, YN, Foo, WC, Maru, D, Thirumurthi, S, Morris, VK, Kopetz, S, Overman, MJ, Ludford, K. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40374594.
2. Zhou T, Short NJ, Jain N, Patel KP, Jabbour EJ, Kantarjian HM, Medeiros LJ, Iorgulescu JB. Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data. Leukemia 39(7):1769-1772, 2025. e-Pub 2025. PMID: 40275068.
3. Ronaghy, A, Crimini, E, Holla, V, Mills Shaw, KR, Doefler, AM, Campbell, E, Yang, RK, Iorgulescu, JB, Patel, KP, McPherson, DD, Ning, J, Meric-Bernstam, F, Karp, DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40460677.
4. Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
5. Ronaghy A, Crimini E, Holla VR, Mills Shaw KR, Doefler AM, Campbell E, Yang RK, Iorgulescu JB, Patel KP, McPherson DD, Ning J, Meric-Bernstam F, Karp DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6):105061, 2025. e-Pub 2025. PMID: 40460677.
6. Gouda MA, Janku F, Yuan Y, Drusbosky LM, Chen AP, Zheng X, Patel K, Hamilton SR, Routbort M, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Coffey B, Little RF, Arteaga CL, O'Dwyer PJ, Flaherty KT, Harris LN, Meric-Bernstam F. Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131). Clin Cancer Res, 2025. e-Pub 2025. PMID: 40388547.
7. Edelman Saul E, Urrutia S, Yang H, Montalban-Bravo G, Tang G, Toruner G, Patel K, Luthra R, Bueso-Ramos C, Wang SA, Chien K, Sasaki K, Atluri H, Goulart H, Thakral B, Garcia-Manero G, Kanagal-Shamanna R. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. J Natl Compr Canc Netw 23(6), 2025. e-Pub 2025. PMID: 40345240.
8. Nahmod KA, Miranda RN, Vega F, Thakral B, Pemmaraju N, Montalban-Bravo G, Loghavi S, Jelloul FZ, Wang W, Wang S, Muzzafar T, Patel K, Bueso-Ramos CE, Medeiros L, Kanagal-Shamanna R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. Leukemia and Lymphoma 66(4):764-772, 2025. e-Pub 2025. PMID: 39704386.
9. Gandhi V, Tantawy S, Aslan B, Manyam G, Iles L, Timofeeva N, Singh N, Jain N, Ferrajoli A, Thompson P, Patel K, Desikan SP, Wierda W. Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. Res Sq, 2025. e-Pub 2025. PMID: 40235506.
10. Wei Q, Toruner GA, Thakral B, Patel KP, Pemmaraju N, Wang SA, Kanagal-Shamanna R, Tang G, Issa GC, Loghavi S, Medeiros L, DiNardo C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes (Basel) 16(3):317, 2025. e-Pub 2025. PMID: 40149468.
11. Wang P, Yang RK, Jelloul FZ, Luthra R, Routbort MJ, Chen H, Loghavi S, Ok CY, Kanagal-Shamanna R, Roy-Chowdhuri S, Medeiros L, Patel KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precis Oncol 9(e2400299), 2025. e-Pub 2025. PMID: 40138600.
12. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
13. Yang, RK, Alvarez, HA, Lucas, AS, Roy Chowdhuri, S, Rashid, A, Chen, H, Ballester, L, Sweeney, K, Routbort, MJ, Patel, KP, Luthra, R, Medeiros, LJ, Toruner, GA. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genetics 290-291:44-50, 2025. e-Pub 2025. PMID: 39700818.
14. Jen W, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia 131(1):e35662, 2025. e-Pub 2025. PMID: 39584789.
15. Subbiah, V, Gouda, MA, Iorgulescu, JB, Dadu, R, Patel, KP, Sherman, S, Cabanillas, ME, Hu, MI, Castellanos, LE, Amini, B, Meric-Bernstam, F, Shen, T, Wu, J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38438731.
16. Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
17. Kim, DH, Jia, F, Patel, KP, Bose, P, Wang, S, Bueso-Ramos, CE, Ok, CY. Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow. Clinical Lymphoma, Myeloma and Leukemia 24(11):e878-e882, 2024. e-Pub 2024. PMID: 39107203.
18. Holla, V, Kahle, M, Kim, SH, Ronaghy, A, Yang, RK, Patel, KP, Routbort, MJ, Overman, MJ, Ileana Dumbrava, EE, Mills Shaw, KR, Karp, DD, Meric-Bernstam, F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39576951.
19. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma 65(9):1325-1334, 2024. e-Pub 2024. PMID: 38749022.
20. El-Dana, F, Garces Narvaez, SA, El-Mallawany, NK, Agrusa, JE, Dreyer, Z, Marcogliese, A, Elghetany, MT, Punia, JN, Ok, CY, Patel, KP, Lopez-Terrada, D, Fisher, KE, Curry, CV. Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma. Pediatric and Developmental Pathology 27(4):348-353, 2024. e-Pub 2024. PMID: 38468555.
21. Sasaki, K, Ravandi-Kashani, F, Kadia, TM, DiNardo, C, Yilmaz, M, Short, NJ, Jabbour, EJ, Patel, KP, Loghavi, S, Pierce, S, Borthakur, G, Kantarjian, HM. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(6):375-381, 2024. e-Pub 2024. PMID: 38431521.
22. Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Nasr, L, Macaron, W, Yilmaz, M, Borthakur, G, Montalban Bravo, G, Garcia-Manero, G, Issa, GC, Chien, KS, Jabbour, EJ, Nasnas, C, Huang, X, Qiao, W, Matthews, JA, Stojanik, CJ, Patel, KP, Abramova, R, Thankachan, J, Konopleva, M, Kantarjian, HM, Ravandi-Kashani, F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML. Journal of Clinical Oncology 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
23. Nowlen, CJ, Daniels, MS, Uzunparmak, B, Ileana Dumbrava, EE, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. Journal of Immunotherapy and Precision Oncology 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
24. Zheng, L, Luthra, R, Alvarez, HA, San Lucas, FA, Duose, D, Wistuba, II, Fuller, GN, Ballester, L, Roy Chowdhuri, S, Sweeney, K, Rashid, A, Yang, RK, Chen, W, Liu, A, Wu, Y, Albarracin, C, Patel, KP, Routbort, MJ, Sahin, AA, Ding, Q, Chen, H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers 16(1), 2024. e-Pub 2024. PMID: 38201434.
25. Diks, J, Tang, Z, Altan, M, Anderson, S, Chen, H, Rashid, A, Yang, RK, Routbort, MJ, Patel, KP, Toruner, GA, Medeiros, LJ, Tang, G, Luthra, R, Roy Chowdhuri, S. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non–small cell lung cancer cytology specimens. Cancer Cytopathology 132(1):41-49, 2024. e-Pub 2024. PMID: 37747438.
26. Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Kadia TM, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
27. Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
28. Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez LA, Pozsgai MJ, McNeely KE, Ha TT, Venugopal P, Arts P, King-Smith S, Cheah JJ, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman ES, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Georges N, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff HY, Ripperger T, Schulte RR, Tawana K, Velloso E, Benedict Y, Kim EMK, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski N, Babic M, Wei AH, Forsyth CJ, Mar Fan H, Lewis I, Cooney JP, Susman R, Fox LC, Blombery P, Singhal D, Hiwase DK, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu PP, Godley LA, Brown AL. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Adv 7(20):6092-6107, 2023. e-Pub 2023. PMID: 37406166.
29. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
30. Iorgulescu, JB, Shaw, LK, Rashid, A, Rao, P, Mandayam, S, Patel, KP, Schmeler, KM, Yang, RK, Msaouel, P. Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant. Current Oncology 30(10):9019-9027, 2023. e-Pub 2023. PMID: 37887551.
31. Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol 98(8):E193-E196, 2023. e-Pub 2023. PMID: 37154083.
32. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
33. Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
34. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
35. Jelloul FZ, Quesada AE, Yang RK, Li S, Wang W, Xu J, Tang G, Yin CC, Fang H, El Hussein S, Khoury J, Bassett RL, Garcia-Manero G, Manasanch EE, Orlowski RZ, Qazilbash MH, Patel KP, Medeiros LJ, Lin P. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol 36(6):100166, 2023. e-Pub 2023. PMID: 36990279.
36. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
37. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
38. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
39. Suknuntha K, Geyer JT, Patel KP, Weinberg OK, Rogers HJ, Lake JI, Lauridsen L, Patel JL, Kluk MJ, Arber DA, Hsi ED, Bagg A, Bueso-Ramos C, Orazi A. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res 127:107033. e-Pub 2023. PMID: 36774789.
40. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. e-Pub 2023. PMID: 36715486.
41. Jabbour E, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel K, Kanagal-Shamanna R, Champlin R, Khouri I, Dellasala S, Pierce SA, Kantarjian H. The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors. Am J Hematol. e-Pub 2023. PMID: 36683287.
42. Xu J, Li S, Yin CC, Patel KP, Tang G, Wang W, Miranda RN, Garces S, Tang Z, Lin P, Medeiros LJ. Classic Hodgkin Lymphoma with Marked Granulomatous Reaction: A Clinicopathologic Study of 20 Cases. Hum Pathol. e-Pub 2022. PMID: 36584716.
43. Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel) 12(1), 2022. e-Pub 2022. PMID: 36671709.
44. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
45. Shuai W, Zuo Z, Li N, Garces S, Jelloul FZ, Ok CY, Li S, Xu J, You MJ, Wang W, Rehder C, Jabbour EJ, Patel KP, Medeiros LJ, Yin CC. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer. e-Pub 2022. PMID: 36583229.
46. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
47. Issa GC, Bidikian A, Venugopal S, Konopleva MY, DiNardo CD, Kadia TM, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. e-Pub 2022. PMID: 36322818.
48. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
49. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
50. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. e-Pub 2022. PMID: 36402146.
51. Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 12(10):144, 2022. e-Pub 2022. PMID: 36307398.
52. Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, Patel KP, Luthra R, Medeiros LJ, Toruner GA. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel) 14(19), 2022. e-Pub 2022. PMID: 36230473.
53. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. e-Pub 2022. PMID: 36087091.
54. Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji RS, Loh ML, Loghavi S, Mullighan CG, Ogawa S, Tefferi A, Papaemmanuil E, Reiter A, Ross DM, Savona MR, Shimamura A, Skoda RC, Sole F, Stone RM, Orazi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. Blood. e-Pub 2022. PMID: 36130297.
55. Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5. e-Pub 2022. PMID: 35787095.
56. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
57. Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. e-Pub 2022. PMID: 35690645.
58. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol 35(5):705, 2022. e-Pub 2022. PMID: 34903824.
59. Short NJ, Kantarjian HM, Ravandi F, Konopleva MY, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang SA, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver NG, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour EJ. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. e-Pub 2022. PMID: 35533262.
60. Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. e-Pub 2022. PMID: 35504958.
61. Fang H, Wang SA, Khoury JD, El Hussein S, Kim DH, Tashakori M, Tang Z, Li S, Hu Z, Jelloul FZ, Patel KP, McDonnell TJ, Kadia T, Medeiros LJ, Wang W. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. e-Pub 2022. PMID: 35511670.
62. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
63. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
64. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
65. Fang H, Toruner GA, Tang Z, Tang G, Weissferdt A, Tashakori M, El Hussein S, Thakral B, Quesada AE, Wang W, Patel KP, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE, Jelloul FZ. Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Ann Diagn Pathol 59:151951. e-Pub 2022. PMID: 35489185.
66. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol 35(4):470-479, 2022. e-Pub 2022. PMID: 34775472.
67. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. e-Pub 2022. PMID: 35467000.
68. Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol 56:151860, 2022. e-Pub 2022. PMID: 34823075.
69. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. e-Pub 2022. PMID: 35074072.
70. El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. e-Pub 2022. PMID: 34992253.
71. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. e-Pub 2022. PMID: 34989420.
72. Kundrod KA, Natoli ME, Chang MM, Smith CA, Paul S, Ogoe D, Goh C, Santhanaraj A, Price A, Eldin KW, Patel KP, Baker E, Schmeler KM, Richards-Kortum R. Sample-to-answer, extraction-free, real-time RT-LAMP test for SARS-CoV-2 in nasopharyngeal, nasal, and saliva samples: Implications and use for surveillance testing. PLoS One 17(2):e0264130, 2022. e-Pub 2022. PMID: 35213596.
73. Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James-Echenique L, Tai CH, Patel KP, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv 5(23):4807-4816, 2021. e-Pub 2021. PMID: 34607348.
74. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5(1):99, 2021. e-Pub 2021. PMID: 34853384.
75. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma:1-4. e-Pub 2021. PMID: 34668451.
76. Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang G. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771519.
77. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
78. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
79. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
80. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
81. Wang SA, Chi Young OK, Kim AS, Lucas F, Morgan EA, Thakral B, Patel S, Nardi V, Patel KM, Weinberg OK, Hasserjian RP. Myelodysplastic Syndromes with No Somatic Mutations Detected by Next-Generation Sequencing Display Similar Features to Myelodysplastic Syndromes with Detectable Mutations. Am J Hematol. e-Pub 2021. PMID: 34416041.
82. Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
83. Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL. The RUNX1 Database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. e-Pub 2021. PMID: 34233450.
84. Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RN. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol. e-Pub 2021. PMID: 34226673.
85. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
86. Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. e-Pub 2021. PMID: 34161631.
87. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian H, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. e-Pub 2021. PMID: 34161603.
88. Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud 7(3), 2021. e-Pub 2021. PMID: 34117074.
89. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. e-Pub 2021. PMID: 34007049.
90. Tang Z, Kanagal-Shamanna R, Tang G, Patel K, Medeiros LJ, Toruner GA. Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leuk Res 108:106616. e-Pub 2021. PMID: 34022744.
91. Ramani NS, Chen H, Broaddus RR, Lazar AJ, Luthra R, Medeiros LJ, Patel KP, Rashid A, Routbort MJ, Stewart J, Tang Z, Bassett R, Manekia J, Barkoh BA, Dang H, Roy-Chowdhuri S. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol 129(5):374-382, 2021. e-Pub 2021. PMID: 33119213.
92. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607, 2021. e-Pub 2021. PMID: 33972549.
93. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
94. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
95. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
96. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
97. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
98. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
99. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2021. PMID: 32561839.
100. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
101. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
102. Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32(2):261-268, 2021. e-Pub 2021. PMID: 33161056.
103. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
104. Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O'Leary TJ, Lo AWI, Chen N, Patel NR, Patel KP, Seliger B, Song M, Monzon FA, Carter AB, Gulley ML, Mockus SM, Phung TL, Feilotter H, Williams HE, Ogino S. Opinion: Standardizing gene product nomenclature-a call to action. Proc Natl Acad Sci U S A 118(3), 2021. e-Pub 2021. PMID: 33408252.
105. Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, Chen H, Rashid A, Lazar A, San Lucas FA, Yao H, Manekia J, Dang H, Barkoh BA, Medeiros LJ, Luthra R, Roy-Chowdhuri S. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. e-Pub 2021. PMID: 33493304.
106. Del Valle Estopinal M, Middleton LP, Esmaeli B, Patel KP, Nowroozizadeh S, Williams MD. Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/β-Catenin Complex and Associated Genetic Alterations. Case Rep Pathol 2021:6628150, 2021. e-Pub 2021. PMID: 34804623.
107. Lyapichev KA, Sakhdari A, Khoury JD, O'Malley DP, El Hussein S, Yin CC, Patel KP, Thakral B, Young KH, Medeiros LJ, Konoplev S. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol 49:151636, 2020. e-Pub 2020. PMID: 32977233.
108. Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N. Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma 61(12):3018-3020, 2020. e-Pub 2020. PMID: 32657180.
109. Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma 61(13):3243-3246, 2020. e-Pub 2020. PMID: 32696696.
110. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
111. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
112. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
113. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
114. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. e-Pub 2020. PMID: 33112940.
115. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
116. Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300-1304, 2020. e-Pub 2020. PMID: 33022638.
117. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327, 2020. e-Pub 2020. PMID: 33087716.
118. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
119. El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour EJ, Medeiros LJ, Khoury JD. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol 44(9):1235-1243, 2020. e-Pub 2020. PMID: 32590457.
120. Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang W. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J 10(8):86, 2020. e-Pub 2020. PMID: 32848129.
121. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
122. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
123. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
124. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
125. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
126. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
127. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
128. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. e-Pub 2020. PMID: 32238878.
129. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
130. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
131. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
132. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
133. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791-803, 2020. e-Pub 2020. PMID: 31932844.
134. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful Lenalidomide Treatment in High Risk Myelodysplastic Syndrome with Germline DDX41 Mutation. Am J Hematol 95(2):227-229, 2020. e-Pub 2020. PMID: 31400013.
135. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
136. Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CY. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2020. PMID: 31804006.
137. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765-774, 2020. e-Pub 2020. PMID: 31742675.
138. Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1):83, 2020. e-Pub 2020. PMID: 32005111.
139. Garces S, Yin CC, Miranda RN, Patel KP, Li S, Xu J, Thakral B, Poppiti RJ, Medina AM, Sriganeshan V, Castellano-Sánchez A, Khoury JD, Garces JC, Medeiros LJ. Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. Mod Pathol. e-Pub 2020. PMID: 31896812.
140. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
141. Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
142. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
143. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
144. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
145. Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res 86:106227, 2019. e-Pub 2019. PMID: 31557598.
146. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
147. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
148. Jain P, Gu J, Kanagal-Shamanna R, Tang Z, Patel KP, Yao H, Fang L, Bao HY, Liu CH, Lin P, Medeiros LJ, Lu X. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res 84:106176, 2019. e-Pub 2019. PMID: 31279181.
149. Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
150. Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk 19(7):431-440.e13, 2019. e-Pub 2019. PMID: 31056348.
151. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
152. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
153. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
154. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
155. Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther 12(2):115-118, 2019. e-Pub 2019. PMID: 29409729.
156. Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros L. Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief 24:104025, 2019. e-Pub 2019. PMID: 31193989.
157. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
158. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348-2351, 2019. e-Pub 2019. PMID: 30796023.
159. Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet 233-234:21-31, 2019. e-Pub 2019. PMID: 31109591.
160. McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol 139(3):728-731, 2019. e-Pub 2019. PMID: 30798855.
161. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. e-Pub 2019. PMID: 30861111.
162. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. e-Pub 2019. PMID: 30902805.
163. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
164. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 30811597.
165. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
166. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2019. PMID: 30508305.
167. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2019. PMID: 30171025.
168. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. e-Pub 2019. PMID: 30577887.
169. Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol 10(1):33-39, 2019. e-Pub 2019. PMID: 28682832.
170. Garces S, Yin CC, Patel KP, Khoury JD, Manning JT, Li S, Xu J, Pina-Oviedo S, Johnson MR, González S, Molgó M, Ruiz-Cordero R, Medeiros LJ. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol 32(1):16-26, 2019. e-Pub 2019. PMID: 30323237.
171. Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta Haematol 141(1):23-27, 2019. e-Pub 2019. PMID: 30463063.
172. Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914014.
173. Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia 10(1038):2698-2701, 2018. e-Pub 2018. PMID: 29884905.
174. Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2018. PMID: 29265180.
175. Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
176. Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
177. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 10(1182):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
178. Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna R. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol 10(1038):1717-1732, 2018. e-Pub 2018. PMID: 29955146.
179. Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova A. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet 10(1016):17-22, 2018. e-Pub 2018. PMID: 30005850.
180. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
181. Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, Chen TX, Geis JA, Oldham W, Matthews J, Kantarjian H, Futreal PA, Patel K, Jones KW, Takahashi K, Eastburn DJ. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res 28(9):1345-1352, 2018. e-Pub 2018. PMID: 30087104.
182. Montes-Moreno S, Routbort MJ, Lohman EJ, Kanagal-Shamanna R, BUeso-Ramos CE, Singh RR, Medieros LJ, Luthra R, Patel KP. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoSONE 13(9), 2018. e-Pub 2018. PMID: 30222780.
183. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol 10(1002):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
184. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 10(1016):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
185. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
186. Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 1158(10):1575-1584, 2018. e-Pub 2018. PMID: 29695638.
187. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
188. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. e-Pub 2018. PMID: 29682723.
189. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1672-1676, 2018. e-Pub 2018. PMID: 29119847.
190. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Haematologica 107(6):689-695, 2018. e-Pub 2018. PMID: 29464484.
191. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
192. shizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. caCancer Research 78(10):2721-2731, 2018. e-Pub 2018. PMID: 29490944.
193. Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KP. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol 42(5):569-577, 2018. e-Pub 2018. PMID: 29635257.
194. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
195. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY 10, 2018. e-Pub 2018. PMID: 29702001.
196. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
197. Middleton LP, Phipps R, Routbort M, Prieto V, Medeiros LJ, Riben M, Contreras A, Kelley J, Patel K, Bingham J, Wagar EA. Fifteen-Year Journey to High Reliability in Pathology and Laboratory Medicine. Am J Med Qual:1062860618759198. e-Pub 2018. PMID: 29512395.
198. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
199. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. e-Pub 2018. PMID: 29464484.
200. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese LE, Ma W, Ma MCJ, DiNardo CD, Pierce SA, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Res. e-Pub 2018. PMID: 29490944.
201. Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, Goswami M, Wang M, Jorgensen JL, Medeiros LJ, Wang SA. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 10(1038):327-336, 2018. e-Pub 2018. PMID: 28984300.
202. Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Jeffrey Medeiros L, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9(12):10259-10271, 2018. e-Pub 2018. PMID: 29535804.
203. Samman Tahhan A, Sandesara P, Hayek SS, Hammadah M, Alkhoder A, Kelli HM, Topel M, O'Neal WT, Ghasemzadeh N, Ko YA, Gafeer MM, Abdelhadi N, Choudhary F, Patel K, Beshiri A, Murtagh G, Kim J, Wilson P, Shaw L, Vaccarino V, Epstein SE, Sperling L, Quyyumi AA. High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes. J Am Heart Assoc 7(5), 2018. e-Pub 2018. PMID: 29467150.
204. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2018. PMID: 29134664.
205. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma:1-4. e-Pub 2018. PMID: 29338567.
206. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Ferrajoli A, Futreal PA, Wierda WG. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. e-Pub 2018. PMID: 29358183.
207. Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JD. Chronic Lymphoproliferative Disorder of NK-cells: A Single-Institution Review with Emphasis on Relative Utility of Multimodality Diagnostic Tools. Eur J Haematol. e-Pub 2018. PMID: 29385279.
208. Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of Cutaneous Pathology 44(12):1075-1079, 2017. e-Pub 2017. PMID: 28885734.
209. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. European journal of haematology 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
210. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
211. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
212. Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, Garces JC, Khoury JD, Yin CC. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Modern pathology : an official journal of the United States and Canadian Academy of Pathology 30(10):1367–1377, 2017. e-Pub 2017. PMID: 28664935.
213. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica 102(10):1709-1717, 2017. e-Pub 2017.
214. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. European journal of haematology 99(6):536-543, 2017. e-Pub 2017.
215. Onaindia A, Medeiros LJ, Patel KP. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Modern Pathology 30(10):1338-1366, 2017. e-Pub 2017. PMID: 28664939.
216. Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of cutaneous pathology 44(12):1078-1079, 2017. e-Pub 2017. PMID: 28885734.
217. Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res 59:105-109, 2017. e-Pub 2017. PMID: 28599188.
218. Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome 59:105-109, 2017. e-Pub 2017.
219. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. British journal of haematology 178(3):403-421, 2017. e-Pub 2017. PMID: 28382648.
220. Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clinical lymphoma, myeloma & leukemia 17:S62-S74, 2017. e-Pub 2017. PMID: 28760304.
221. Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Courty J, Young KH, Sehgal L, Samaniego F. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 10:63-69, 2017. e-Pub 2017. PMID: 28690315.
222. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
223. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International journal of molecular sciences 18(8), 2017. e-Pub 2017. PMID: 28933735.
224. Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. American Journal of Hematology 92(8):E175-E177, 2017. e-Pub 2017. PMID: 28494520.
225. Rashmi Kanagal-Shamanna MD, Preetesh Jain MD, DM, PhD, Koichi Takahashi MD, Nicholas J Short MD, Guilin Tang MD, PhD, Ghayas C Issa MD, Farhad Ravandi MD, Guillermo Garcia-Manero MD, Cameron C Yin MD, PhD, PhD RL, Keyur P Patel MD, PhD, Joseph D Khoury MD, Guillermo Montalban-Bravo MD, Koji Sasaki MD, Tapan M Kadia MD, Gautam Borthakur MD, Marina Konopleva MD, PhD, Nitin Jain MD, Rebecca Garris MS, Sherry Pierce BSN, BA, William Wierda MD, Zeev Estrov MD, Jorge Cortes MD, Susan O'Brien MD, Hagop M Kantarjian MD, Elias Jabbour MD. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):37173724, 2017. e-Pub 2017. PMID: 28608976.
226. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv 1(15):1031-1036, 2017. e-Pub 2017. PMID: 29296745.
227. Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CC. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 30:734-744, 2017. e-Pub 2017. PMID: 28084334.
228. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood, 2017. e-Pub 2017. PMID: 28674026.
229. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. American Journal of Hematology 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
230. Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN. Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol 41(4):431-445, 2017. e-Pub 2017. PMID: 28248813.
231. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165-e175, 2017. e-Pub 2017. PMID: 28291640.
232. Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RR. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet 212-213:24-31, 2017. e-Pub 2017. PMID: 28449808.
233. Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra R. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol 30(4):499-508, 2017. e-Pub 2017. PMID: 28084342.
234. Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn 19(2):313-327, 2017. e-Pub 2017. PMID: 28188106.
235. Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. J Neuropathol Exp Neurol 76(3):179-188, 2017. e-Pub 2017. PMID: 28395087.
236. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology 92(3):238-243, 2017. e-Pub 2017.
237. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
238. Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, Chen W, Hatfield DZ, Medeiros LJ, Singh RR. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn 19(2):255-264, 2017. e-Pub 2017. PMID: 28017569.
239. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
240. Chen Z, Medeiros LJ, Kantajian HM, Zheng L, Gong Z, Patel KP, Xiong H, Wang W, Cortes JE, Hu S. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J 7(2):e521, 2017. e-Pub 2017. PMID: 28157214.
241. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572-581, 2017. e-Pub 2017. PMID: 27919910.
242. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
243. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. American Journal of Hematology 18(1):100-111, 2017. e-Pub 2017. PMID: 27923552.
244. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
245. Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra R. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One 12(8):e0181968, 2017. e-Pub 2017. PMID: 28767674.
246. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
247. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. e-Pub 2016. PMID: 27727470.
248. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. e-Pub 2016. PMID: 27741352.
249. Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol 29(10):1221-31, 2016. e-Pub 2016. PMID: 27443511.
250. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn 18(5):676-87, 2016. e-Pub 2016. PMID: 27392636.
251. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pretransplantion minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. e-Pub 2016. PMID: 27540139.
252. Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma 57(8):1969-73, 2016. e-Pub 2016. PMID: 26700872.
253. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
254. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. e-Pub 2016. PMID: 27463065.
255. Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 16(7):395-403.e1, 2016. e-Pub 2016. PMID: 27268124.
256. Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JL. Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med 140(7):672-4, 2016. e-Pub 2016. PMID: 26653363.
257. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk 16(7):417-428.e2, 2016. e-Pub 2016. PMID: 27210295.
258. Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JL. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med 140(7):675-7, 2016. e-Pub 2016. PMID: 26653364.
259. Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant 22(7):1218-26, 2016. e-Pub 2016. PMID: 27058617.
260. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
261. Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol 52:61-7, 2016. e-Pub 2016. PMID: 26980021.
262. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. Journal of the National Comprehensive Cancer Network 14(6):787-792, 2016. e-Pub 2016. PMID: 27283170.
263. Hong M, Hao S, Patel KP, Kantarjian HM, Garcia-Manero G, Yin CC, Medeiros LJ, Lin P, Lu X. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet 209(5):205-14, 2016. e-Pub 2016. PMID: 27134073.
264. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
265. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C, Reporting Committee MOTCB, American Pathologists CO. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Arch Pathol Lab Med. e-Pub 2016. PMID: 27081879.
266. Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Jeffrey Medeiros L, Wang SA. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma 57(4):812-9, 2016. e-Pub 2016. PMID: 26293512.
267. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C, Reporting Committee MOTCB, American Pathologists CO. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Arch Pathol Lab Med. e-Pub 2016. PMID: 27081876.
268. Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. J Clin Oncol 32(7):e57-60, 2016. e-Pub 2016. PMID: 24982452.
269. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol 95(Suppl. 1):361A-361A, 2016. e-Pub 2016. PMID: 27124925.
270. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
271. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
272. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-8, 2016. e-Pub 2016. PMID: 26883102.
273. Mehrotra M, Patel KP. High-Resolution Melt Curve Analysis in Cancer Mutation Screen. Methods in molecular biology 1392:63-69, 2016. e-Pub 2016. PMID: 26843047.
274. Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen H. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol 145(2):222-37, 2016. e-Pub 2016. PMID: 27124905.
275. Gu J, Reynolds A, Fang L, DeGraffenreid C, Sterns K, Patel KP, Medeiros LJ, Lin P, Lu X. Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases. Mol Cytogenet 9:84, 2016. e-Pub 2016. PMID: 27895713.
276. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
277. Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Mol Cancer Ther 14(12):2887-95, 2015. e-Pub 2015. PMID: 26438153.
278. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
279. Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical Validation of a Multi-Purpose Assay for Detection, Genotyping and Monitoring of CALR Mutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology 144(5):746-755, 2015. e-Pub 2015. PMID: 26486739.
280. Ai DI, Liu W, Lu G, Patel KP, Chen ZI. Extramedullary blast crisis as initial presentation in chronic myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report. Mol Clin Oncol 3(6):1319-1322, 2015. e-Pub 2015. PMID: 26807241.
281. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
282. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet 208(11):571-4, 2015. e-Pub 2015. PMID: 26382622.
283. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
284. Mehrotra M, Patel KP, Chen T, Miranda RN, Wang Y, Zuo Z, Muddasani R, Mishra BM, Abraham R, Luthra R, Lu G. Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion. Clin Lymphoma Myeloma Leuk 15(8):496-505.e2, 2015. e-Pub 2015. PMID: 26027540.
285. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
286. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-6, 2015. e-Pub 2015. PMID: 26016821.
287. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-7, 2015. e-Pub 2015. PMID: 26124496.
288. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol 90(7):E134-5, 2015. e-Pub 2015. PMID: 25801490.
289. Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors affecting the success of next-generation sequencing in cytology specimens. MODERN PATHOLOGY 28(Suppl. 2):105A-105A, 2015. e-Pub 2015. PMID: 26230354.
290. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
291. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clin Cancer Res 21(11):2644-2651, 2015. e-Pub 2015. PMID: 25695693.
292. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2015. PMID: 25630528.
293. Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary Mutations as Mediators of Resistance to Targeted Therapy in Leukemia. Blood 125(21):3360-3363, 2015. e-Pub 2015. PMID: 25795921.
294. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3, 2015. e-Pub 2015. PMID: 25999449.
295. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. e-Pub 2015. PMID: 26014291.
296. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8(45), 2015. e-Pub 2015. PMID: 25952993.
297. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol 42(5):308-317, 2015. e-Pub 2015. PMID: 25754356.
298. Berkova Z, Wang S, Sehgal L, Patel KP, Prakash O, Samaniego F. Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice. Histol Histopathol 30(5):559-568, 2015. e-Pub 2015. PMID: 25301266.
299. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. e-Pub 2015. PMID: 26015395.
300. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 46(4):558-69, 2015. e-Pub 2015. PMID: 25666664.
301. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol 00(00). e-Pub 2015. PMID: 25808231.
302. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJ. Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. Am J Surg Pathol 308(5):H447-H455, 2015. e-Pub 2015. PMID: 25634750.
303. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-54, 2015. e-Pub 2015. PMID: 25573287.
304. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
305. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2015. PMID: 26687423.
306. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia. J Natl Compr Canc Netw 13(1):19-22, 2015. e-Pub 2015. PMID: 25583766.
307. Gu J, Patel KP, Bai B, Liu CH, Tang G, Kantarjian HM, Tang Z, Abraham R, Luthra R, Medeiros LJ, Lin P, Lu X. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet 8:68, 2015. e-Pub 2015. PMID: 26300976.
308. Mehrotra M, Luthra R, Ravandi F, Sargent RL, Barkoh BA, Abraham R, Mishra BM, Medeiros LJ, Patel KP. Identification of Clinically Important Chromosomal Aberrations in Acute Myeloid Leukemia by Array-Based Comparative Genomic Hybridization. Leuk Lymphoma 55(11):2538-2548, 2014. e-Pub 2014. PMID: 24446873.
309. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111(10):2014-2023, 2014. e-Pub 2014. PMID: 25314059.
310. Loghavi S, Curry JL, Torres-Cabala CA, Ivan D, Patel KP, Mehrotra M, Bassett R, Prieto VG, Tetzlaff MT. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. MODERN PATHOLOGY 27(11):1468-1478, 2014. e-Pub 2014. PMID: 24743221.
311. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros L, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A , FLT3 and NPM1 mutations. J Hematol Oncol 7(1):74. e-Pub 2014. PMID: 25281355.
312. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090-2, 2014. e-Pub 2014. PMID: 24854988.
313. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
314. Mehrotra M, Medeiros LJ, Luthra R, Sargent RL, Yao H, Barkoh BA, Singh R, Patel KP. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol 45(10):1995-2005, 2014. e-Pub 2014. PMID: 25128227.
315. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123(17):2645-51, 2014. e-Pub 2014. PMID: 24627528.
316. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol 141(4):559-72, 2014. e-Pub 2014. PMID: 24619758.
317. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 99(3):465-473, 2014. e-Pub 2014. PMID: 24142997.
318. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next Generation Sequencing-Based Multi-Gene Mutation Profiling of Solid Tumors Using Fine Needle Aspiration Samples: Promises and Challenges for Routine Clinical Diagnostics. Mod Pathol 27(2):314-27, 2014. e-Pub 2014. PMID: 23907151.
319. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, James You M, Miranda RN, Garcia-Manero G, Kantarjian HM, Jeffrey Medeiros L, Luthra R, Khoury JD. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol 88(12). e-Pub 2014. PMID: 24446311.
320. Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SA. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28(1):185-9, 2014. e-Pub 2014. PMID: 23787392.
321. Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol 41(1):51-7, 2014. e-Pub 2014. PMID: 24151865.
322. Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
323. Korivi BR, Jensen CT, Patnana M, Patel KP, Bathala TK. A rare presentation of lymphoma of the cervix with cross-sectional imaging correlation. Case Rep Radiol 2014:157268, 2014. e-Pub 2014. PMID: 24864220.
324. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 2013. e-Pub 2013. PMID: 23940084.
325. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 122(23):3784-6, 2013. e-Pub 2013. PMID: 24068492.
326. Jain P, Le X, Young KH, Patel KP, Wang S, Pei L, Barron LL, Abruzzo L, O'Brien S. Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 13(5):606-9, 2013. e-Pub 2013. PMID: 23763914.
327. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R. Clinical Validation of a Next Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-related Genes. J Mol Diagn 15(5):607-22, 2013. e-Pub 2013. PMID: 23810757.
328. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol 37(8):1290-7, 2013. e-Pub 2013. PMID: 23774171.
329. Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma 54(7):1552, 2013. e-Pub 2013. PMID: 23121011.
330. Al-Ibraheemi A, Kanagal-Shamanna R, Patel KP, Konoplev SN, Mehta P, Medeiros LJ, Miranda RN. Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. J Cutan Pathol 40(6):573-9, 2013. e-Pub 2013. PMID: 23495765.
331. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 28(1), 2013. e-Pub 2013. PMID: 23774633.
332. Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC. Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples. Genet Test Mol Biomarkers 17(5):429-37, 2013. e-Pub 2013. PMID: 23537216.
333. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1,112 Cases of Melanoma. J Mol Diagn 15(2):220-6, 2013. e-Pub 2013. PMID: 23273605.
334. Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJ. TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol 26(2):195-203, 2013. e-Pub 2013. PMID: 22936064.
335. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2013. PMID: 23115106.
336. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819-22, 2012. e-Pub 2012. PMID: 22605576.
337. Dinardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Blood 120(21), 2012. e-Pub 2012. PMID: 24138309.
338. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. Blood 120(21), 2012. e-Pub 2012. PMID: 24004182.
339. Nicholson KM, Patel KP, Duvic M, Prieto VG, Tetzlaff MT. Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol 39(9):866-71, 2012. e-Pub 2012. PMID: 22809282.
340. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn 14(4):336-45, 2012. e-Pub 2012. PMID: 22642896.
341. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol 138(1):153-6, 2012. e-Pub 2012. PMID: 22706871.
342. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 2012. e-Pub 2012. PMID: 22020636.
343. Deqin M, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med 136(5):510-6, 2012. e-Pub 2012. PMID: 22540299.
344. Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ, Luthra R. Diagnostic Testing for IDH1 and IDH2 variants in Acute Myeloid Leukemia: An Algorithmic Approach Using High Resolution Melting Curve Analysis. J Mol Diagn 13(6):678-86, 2011. e-Pub 2011. PMID: 21889610.
345. Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S17-24, 2011. e-Pub 2011. PMID: 22035742.
346. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35-45, 2011. e-Pub 2011. PMID: 21173122.
347. Patel KP, Pan Q, Wang Y, Maitta RW, Du J, Xue X, Lin J, Ratech H. Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements. J Mol Diagn 12(2):226-37, 2010. e-Pub 2010. PMID: 20181819.
348. Ost MC, Patel KP, Rastinehad AR, Chu PY, Anderson AE, Smith AD, Lee BR. Pneumoperitoneum with carbon dioxide inhibits macrophage tumor necrosis factor-alpha secretion: source of transitional-cell carcinoma port-site metastasis, with prophylactic irrigation strategies to decrease laparoscopic oncologic risks. J Endourol 22(1):105-12, 2008. e-Pub 2008. PMID: 18315481.
349. Lisovsky M, Patel K, Cymes K, Chase D, Bhuiya T, Morgenstern N. Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch Pathol Lab Med 131(8):1304-11, 2007. e-Pub 2007. PMID: 17683193.
350. Yang C, Patel K, Harding P, Sorokin A, Glass WF. Regulation of TGF-beta1/MAPK-mediated PAI-1 gene expression by the actin cytoskeleton in human mesangial cells. Exp Cell Res 313(6):1240-50, 2007. e-Pub 2007. PMID: 17328891.
351. Herling, M, Patel, KP, Khalili, J, Schlette, EJ, Kobayashi, R, Medeiros, LJ, Jones, D. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20(2):280-285, 2006. e-Pub 2006. PMID: 16341048.
352. Li L, Hsu P, Patel K, Saffari Y, Ashley I, Brody J. Polyclonal plasma cell proliferation with marked hypergammaglobulinemia and multiple autoantibodies. Ann Clin Lab Sci 36(4):479-84, 2006. e-Pub 2006. PMID: 17127739.
353. Patel K, Harding P, Haney LB, Glass WF. Regulation of the mesangial cell myofibroblast phenotype by actin polymerization. J Cell Physiol 195(3):435-45, 2003. e-Pub 2003. PMID: 12704653.
354. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr GL. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158(4):1491-502, 2001. e-Pub 2001. PMID: 11290567.
355. Jelloul FZ, Yang R, Wang P, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd F, Bassett R, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. NOTCH1 mutations in Chronic Lymphocytic Leukemia. Leukemia Research.

Invited Articles

1. Gupta SK, Viswanatha DS, Patel KP. Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing. Front Cell Dev Biol 8:357, 2020. e-Pub 2020. PMID: 32509784.
2. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. e-Pub 2016. PMID: 27283170.
3. Kanagal-Shamanna R, Singh RR, Routbort MJ, Patel KP, Medeiros LJ, Luthra R. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev Mol Diagn 16(4):461-72, 2016. e-Pub 2016. PMID: 26765348.
4. Singh R, Luthra R, Routbort MJ, Patel KP, Medeiros JL. Implementation of next generation sequencing in clincal molecular diagnostic laboratories: advantages, challenges and potential. Expert Review of Precision Medicine and Drug Development 1(1):109-120, 2016. e-Pub 2016.

Review Articles

1. Iorgulescu, JB, Medeiros, LJ, Patel, KP. Predictive and prognostic molecular biomarkers in lymphomas. Pathology 56(2):239-258, 2024. e-Pub 2024. PMID: 38216400.
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703-1719, 2022. e-Pub 2022. PMID: 35732831.
3. Aitken MJL, Ravandi F, Patel KP, Short NJ. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol 14(1):137, 2021. e-Pub 2021. PMID: 34479626.
4. Fang H, Medeiros LJ, Tang Z, Wang W, Ok CY, Patel KP, Khoury JD, Thakral B. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol 50:151649, 2021. e-Pub 2021. PMID: 33189964.
5. Patel K, Bhuiya T, Chen S, Kenan S, Kahn L. Epidermal inclusion cyst of phalanx: a case report and review of the literature. Skeletal Radiol 35(11):861-3, 2006. e-Pub 2006. PMID: 16416148.

Other Articles

1. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME Erratum. JCO Precision Oncology 9, 2025. PMID: 40632979.
2. Medeiros, LJ, Marques-Piubelli, ML, Sangiorgio, VF, Ruiz-Cordero, R, Vega Vazquez, F, Feldman, AL, Chapman, JR, Clemens, MW, Hunt, KK, Evans, MG, Khoo, C, Lade, S, Silberman, M, Morkowski, JJ, Pina, EM, Mills, DC, Bates, CM, Magno, WB, Sohani, AR, Sieling, BA, O'Donoghue, JM, Bacon, CM, Patani, N, Televantou, D, Turner, SD, Johnson, LL, MacNeill, F, Wotherspoon, A, Iyer, SP, Malpica Castillo, LE, Patel, KP, Xu, J, Miranda, R Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants. Modern Pathology 36(12), 2023. PMID: 37948938.
3. Patel K Modulation of TGFβ-Induced PAI-1 expression by changes in actin polymerization in human mesangial cells. Doctoral Dissertation, Eastern Virginia Medical School and Old Dominion University, Norfolk, Virginia, 2006.

Abstracts

1. Rivera D, Kanarjian H, Kadia T, Daver N, DiNardo C, Patel K, Loghavi S, Short N, Yilmaz M, Jabbour E, Garcia-Manero G, Konopleva M, Borthakur G, Ravandi F. Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 21(Supplement 1):S301-S302, 2021. e-Pub 2021.
2. Jelloul FZ, Yang R, Li SY, Tang GL Patel K, Medeiros LJ, Lin P. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Myeloma Patients in The Era of Novel Therapies: A Study of 60 Patients. LABORATORY INVESTIGATION 101(Supplement 1):847-848, 2021. e-Pub 2021.
3. Hussein S, DiNardo C, Khoury J, Fang H, Lyapichev K, Garces S, Kanagal-Shamanna R, Ok CY, Patel K, Routbort M, Medeiros LJ, Wang S, Loghavi S. Emerging WT1mut Clones Contribute to Relapse in NPM1mut AML Patients. LABORATORY INVESTIGATION 101(Supplement 1):818-819, 2021. e-Pub 2021.
4. Gunther JR, Dabaja B, Fang P, Anakwenze CP, Manasanch EE, Lee H, Patel K, Kaufman G, Thomas S, Orlowski R, Weber D, Wang XA, Amini B, Lin P, Pinnix CC. Management and Long-Term Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 108(Issue 3/ Supplement S):E756, 2020. e-Pub 2020.
5. Yang R, Tang Z, Tang G, Toruner G, Yin C, Wang W, Hu S, Zuo Z, Patel, K, Khoury J, Medeiros L. Atypical CBFB FISH Signal Patterns Warrant Further Investigation for a True CBFB Rearrangement: An Analysis of 2,425 CBFB FISH Tests. JOURNAL OF MOLECULAR DIAGNOSTICS 22(Issue 11/ Supplement S):S22-S23, 2020. e-Pub 2020.
6. Khanlari M, Loghavi S, Wang S, El Hussein S, Tashakori M, Bueso-Ramos C, Yin CC, Kanagal-Shamanna R, Khoury J, Medeiros LJ, Patel K, Popat U, Konoplev S. Importance of Bone Marrow Morphologic Features for Surveillance of Patients with Myelofibrosis Following Molecular Clearance after Stem Cell Transplant. MODERN PATHOLOGY 33(Supplement 2):1322, 2020. e-Pub 2020.
7. Khanlari M, Loghavi S, Wang S, El Hussein S, Tashakori M, Bueso-Ramos C, Yin CC, Kanagal-Shamanna R, Khoury J, Medeiros LJ, Patel K, Popat U, Konoplev S. Importance of Bone Marrow Morphologic Features for Surveillance of Patients with Myelofibrosis Following Molecular Clearance after Stem Cell Transplant. LABORATORY INVESTIGATION 100(Supplement 1):1322, 2020. e-Pub 2020.
8. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
9. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
10. Kanagal-Shamanna, R, Luthra, R, Routbort, M J, Singh R, Floyd K, Abraham R, Hai S, Yin C, Zuo Z, Ok CY, Loghavi S, Medeiros L, Patel KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):964-964, 2017. e-Pub 2017.
11. Duose D, Lan CY, Luthra R, WistubaII, Jain N, Konopleva M, Patel KP, . Validation of a Next Generation Sequencing-Based Assay to Detect Recurrent Translocations in Ph-Like Acute Lymphoblastic Leukemia. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):959-959, 2017. e-Pub 2017.
12. Ruiz-Cordero R, Chen, W, Flyod KC, Rodriquez S, Galbincea J, Barjoh B, Routbort M, Luthra R, Singh R, Hatfireld D, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, Medeiros J, Patel KP. Breaking the Turnaround Time Barrier in Next Generation Sequencing Based Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):997-998, 2017. e-Pub 2017.
13. Fang L, Lu X, Hu S, Tang Z, Luthra R, Routbort, Patel KP, Wang R, Broaddus R, Chen H. MET Amplification Predicts Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients with Sensitive EGFR Mutation. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1032-1032, 2017. e-Pub 2017.
14. Hendrickson C, Bany A, Patel K, Huang C, Ryder M, Garlick R, Davis L, Anekella B. Reliable Interpretation of NGS Data Using Well-Established, Highly Multiplexed Reference Materials. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1053-1053, 2017. e-Pub 2017.
15. Barry AJ, Hendrickson C, Patel K, Emerman A, Bowman S, Acott A, Elfe C, Stewart F, Russello S, Davis T. Pre-Designed Gene Content Enables Rapid Deployment of High Quality Customized Enrichment Panels. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1020-1020, 2017. e-Pub 2017.
16. Mallampati S, Duose D, Mehrotra M, Lan C, Windham JP, Wistuba II, Verstovsek S, Luthra R, Patel KP. A Balanced Formulation of Dimethyl Sulfoxide and Bovine Serum Albumin Provides Highly Uniform Coverage of CEBPA in a Droplet PCR-Based NGS Panel. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):970-970, 2017. e-Pub 2017.
17. Barkoh BA, Mehrotra M, Singh RR, Yubitza L, Vidal D, Zalles S, Hannigan B, Bolivar A, Dzifa D, Chen W, Harmon MA, Patel KP, Routbourt, Shamanna RK, Wistuba I, Medeiros J, Luthra R. Validation of a Single-Gene Next-Generation Sequencing Assay for TP53 Mutation Detection in Solid Tumor FFPE Samples in CLIA Laboratory Using Illumina MiSeq. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1031-1031, 2017. e-Pub 2017.
18. Yemelyanova A, Routbort MJ, Chen H, Rashid A, Chowdhuri SR, Lazar AJ, Manekia J, Mohammad M, Mantha G, Singh R, Luthra R, Medeiros JL, Patel KP. Tumor in Normal or Normal in Tumor: What to Do When Somatic Mutations Are Detected in "Normal" Germline Control Used for NGS-Based Targeted Somatic Mutation Testing 19(6):1027-1027, 2017. e-Pub 2017.
19. Mehortra M, Duose D, Singh RR, Lan C, Barkoh BA, Routhort MJ, Patel KP, Medieros LJ, Kopetz S, Wistuab II, Luthra R. Ultra-Sensitive Tag Sequencing for Detection of Low Level Somatic Alterations in Plasma Cell Free DNA of Metastatic Colorectal Tumors on Ion S5XL Platform 19(6):1014-1014, 2017. e-Pub 2017.
20. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. The American Society of Hematology 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
21. Olar A, Broaddus R, Routbort M, Roy-Chowdhuri S, Hodges KB, Singh RR, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Medeiros JL, Hamilton SR, Luthra R, Patel KP. Value of paired tumor-normal analysis in solid tumor genotyping by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):1005, 2016. e-Pub 2016.
22. Patel KP, Barkoh BA, Lewing C, Mantha GS, Broaddus R, Routbort MJ, Middleton LP, Phipps RA, Hamilton SR, Medeiros L, Luthra R. Transforming a clinical molecular diagnostics laboratory into a high reliability organization. Journal of Molecular Diagnostics 18(6):1045, 2016. e-Pub 2016.
23. Mehrotra M, Singh RR, Barkoh BA, Duose DY, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Comparison of Ultrasensitive Droplet Digital PCR and MassARRAY Platforms for Plasma Cell-Free DNA Genotyping. Journal of Molecular Diagnostics 18(6):1046-1047, 2016. e-Pub 2016.
24. Mehrotra M, Singh RR, Loghavi S, Barkoh BA, Simien C, Hernandez M, Manekia J, Behrens C, Routbort MJ, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Ultradeep sequencing using semiconductor-based high-throughput Next- Generation sequencing platforms for cell-free DNA genotyping in patients with solid tumors. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
25. Chen H, Routbort MJ, Rashid A, Roy-Chowdhuri S, Patel KP, Lazar A, Broaddus R, Manekia J, Singh R, Luthra R, Yemelyanova A. Challenges in Next-Generation sequencing analysis of somatic mutations in transplant patients. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
26. Lee S, Broaddus RR, Pattanaprichaku P, Singh RR, Routbort M, Patel KP, Luthra R, Rashid A, Chen H. Molecular characterization of appendiceal mucinous neoplasms: Stratification of KRAS, GNAS, and TP53 mutations by tumor grade. Journal of Molecular Diagnostics 18(6):1001, 2016. e-Pub 2016.
27. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin C, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros L, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):961, 2016. e-Pub 2016.
28. Mehrotra M, Hernandez M, Simien C, Barkoh BA, Bolivar AM, Shi X, Singh RR, Gentles K, Abraham R, Rodriguez S, Cook P, Giffard R, Lentz PS, Patel KP, Kopetz S, Medeiros LJ, Wistuba II. Study of Pre-analytic Parameters for Standardization of Cell-Free DNA Isolation from Plasma in a CLIA-approved Molecular Diagnostics Laboratory. Journal of Molecular Diagnostics 18(6):1019, 2016. e-Pub 2016.
29. Mehrotra M, Luthra R, Wistuba II, Chen W, Barkoh BA, Montes-Moreno S, Burns C, Dailey D, Bolivar A, Routbort MJ, Medeiros L, Patel KP, Singh RR, Kanagal-Shamanna R. "Single-Gene" next-generation sequencing-based assay for detection of low-level TP53 mutations. Journal of Molecular Diagnostics 18(6):1047-1048, 2016. e-Pub 2016.
30. Roy-Chowdhuri S, Routbort MJ, Singh R, Broaddus R, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Manekia J, Chen W, Medeiros LJ, Hamilton SR, Luthra R, Patel KP. SNP Signature-Based Sample Identification as a Patient Safety Tool in NGS-Based Targeted Oncologic Testing. Journal of Molecular Diagnostics 18(6):1049, 2016. e-Pub 2016.
31. Loghavi S, Routbort MJ, Kanagal-Shamanna R, Wang SA, Khoury JD, Ok C, Yin CC, Singh RR, Zuo Z, Bueso-Ramos CE, Medeiros L, Luthra R, Patel KP. Myeloid neoplasms with recurrent GNAS mutations. Journal of Molecular Diagnostics 18(6):960, 2016. e-Pub 2016.
32. Luthra R, Singh RR, Lazar AJ, Wang W, Meis JM, Patel KP, Routbort MJ, Panditi DD, Yau J, Hatfield DZ, Medeiros J. A Nanofluidics-Based High Throughput Real-Time PCR Analysis for Gene Fusions in Sarcomas. Journal of Molecular Diagnostics 18(6):1003-1004, 2016. e-Pub 2016.
33. Singh RR, Hatfield DZ, Reddy NG, Shamanna RK, Routbort M, Galbincea JM, Stewart J, Wierda WG, Medeiros L, Luthra R, Patel KP. Development of a targeted Next-Generation Sequencing (NGS) panel for prognostication and detection of treatment resistance in patients with Chronic Lymphocytic Leukemia (CLL). Journal of Molecular Diagnostics 18(6):951, 2016. e-Pub 2016.
34. Yabe M, Medeiros LJ, Tang GL, Wang SA, Patel KP, Routbort MJ, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen WV, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod T, Davanlou M, Li SY, Young KH, Miranda RN. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Human Pathology 50:109-117, 2016. e-Pub 2016.
35. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 45 Cases of Newly Diagnosed Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29(2):352A, 2016. e-Pub 2016.
36. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 50 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myelodysplastic Syndrome by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29(2):350A-351A, 2016. e-Pub 2016.
37. Ghosh K, Hodjat P, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 117 Cases Newly Diagnosed Myelodysplastic Syndrome: IPSS-R High and Very High Risk by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29(2):346a-347a, 2016. e-Pub 2016.
38. Lu XY, Reynolds A, Konopleva SN, Wang S, Tang GL, Tang ZY, Zweidler-McKay PA, Jorgensen JL, Patel KP, Medeiros LJ, Lin P, Konopleva M, Jain NT. Clinical Implementation of a FISH Panel and Testing Algorithm for Diagnosis of Ph-like B-cell Acute Lymphoblastic. Modern Pathology 29(2):360A-361A, 2016. e-Pub 2016.
39. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 122 Cases of Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29(2):351A, 2016. e-Pub 2016.
40. Salim AA, Luthra R, Singh R, Patel KP, Routbort M, Barkoh BA, Manekia J, Chowdhuri SR, Broaddus R, Chen H. Pre-Analytical Factors Involved in the Clinical Analysis of a Comprehensive Next-Generation Sequencing Panel. Modern Pathology 29(2):504A, 2016. e-Pub 2016.
41. Quesada A, Luthra R, Patel KP, Singh R, Routbort M, Loghavi S, Khoury JD, Medeiros J, Bueso-Ramos CE, Kanagal-Shamanna R. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. Modern Pathology 29(2):371A, 2016. e-Pub 2016.
42. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 8 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myeloproliferative Neoplasms by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29(2):351A, 2016. e-Pub 2016.
43. OK C, Yang H, Villarreal JC, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros JL, Luthra R, Patel KP. Development of a Decision Support System for Specimen Accessioning and Uniform Triaging of Oncologic Molecular Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):803-804, 2015. e-Pub 2015.
44. Chen WV, Reddy N, Jiao O, Suh E, Galbincea J, Singh RR, Patel KP, Luthra R, Routbort M. A Custom HiSeq Bioinformatics Pipeline for TruSeq Based Next-Generation Sequencing Analysis. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):809-809, 2015. e-Pub 2015.
45. Singh RR, Paladugu AV, Jeter KE, Manekia JH, Routbort MJ, Barkoh BA, Patel KP, Luthra R. Comparison of Ion PGM and Proton Platforms for Targeted Hotspot Mutation Analysis. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):822-823, 2015. e-Pub 2015.
46. Almohammedsalim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):773-773, 2015. e-Pub 2015.
47. Chen H, Lu X, Singh R Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort MJ, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative Assessment of ESR, PGR and Genome-Wide Copy Number Aberrations in Advanced Breast Cancer by SNP Microarray. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):840-840, 2015. e-Pub 2015.
48. Bole MD, Pepper RC, Raju S, Roth M, Veliyathu JJ, Bhakta YI, Lewing C, Mantha GS, Luthra R, Barkoh NA, Patel KP. Implementation of a Patient Safety Committee in a Clinical Laboratory. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):811-812, 2015. e-Pub 2015.
49. Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros L, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):766-767, 2015. e-Pub 2015.
50. Routbort MJ, Villareal J, Mantha G, Reddy N, Harmon A, Lui W, Riggins D, Patel KP, Luthra R. High Throughput, High Fidelity Sample Management Using Robotic Tube Labeling and Scanning with a Generalizable Software Toolkit. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):811-811, 2015. e-Pub 2015.
51. OK CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowduri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros JL, Singh RR, Routbort MJ, Luthra R, Patel KP. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):810-810, 2015. e-Pub 2015.
52. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21), 2014. e-Pub 2014.
53. Chen H, Singh R, Luthra R, Routbort M, Patel KP, Goswami R, Abraham R, Dang HD, Aldape K, Broaddus R. CSF1R Amplification in Poorly Differentiated Colorectal Adenocarcinoma with Neuroendocrine Differentiation. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):770-771, 2014. e-Pub 2014.
54. Roy-Chowdhuri S, Patel KP, Chen W, Lazar AJ, Broaddus R, Aldape K, Singh RR, Luthra R, Routbort M. BRAF p.V600E Mutation Detection Is Independent of Estimated Sample Tumor Percentage in a Large Cohort of Melanoma Samples Evaluated by Next-Generation Sequencing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):768-768, 2014. e-Pub 2014.
55. Goswami RS, Luthra R, Patel KP, Routbort MJ, Singh RR, Dang HD, Barkoh BA, Yao H, Aldape KD, Broaddus RR< Chen H. Factors Affecting the Success of Next-Generation Sequencing Analysis in Solid Tumors. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):778-778, 2014. e-Pub 2014.
56. Patel KP, Routbort M, Aldape K, Broaddus R, Lazar A, Chowdhuri SR, Rashid A, Singh R, Zuo Z, Chen H, Shamanna RK, Goswami R, Jabbar K, Barkoh B, ManekiaJ, Medeiros L, Luthra R. Development of a Quality Assurance Framework for Clinical Reporting of. Next-Generation Sequencing-Based Molecular Oncology Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):778-778, 2014. e-Pub 2014.
57. Roy-Chpwdhuri S, Goswami RS, Chen H, Routbort M, Patel KP, Aldape K, Lazar AJ, Broaddus R, Singh RR, Luthra R, Kanagal-Shamanna R. Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) Mutations in Solid Organ Malignancies by Next-Generation Sequencing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):767-767, 2014. e-Pub 2014.
58. Meric-Bersram F, Brusco L, Kopetz S, Davies M, Routbort M, Piha-Paul SA, Alvarez R, Khose S, DeGroot J, Ravi V, Janku F, Hong D, Li Y, Luthra R, Patel KP, Broaddus R, Shaw K, Mendelsohn J, Mills GB. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. EUROPEAN JOURNAL OF CANCER 50(3-3), 2014. e-Pub 2014.
59. Routbort MJ, Patel KP, Harmon MA, Singh RR, Chen WV, Luthra R. Managing Software Change in the Next-Generation Sequencing Lab: Tools and Approaches to in Silico Validation. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):780-781, 2014. e-Pub 2014.
60. Shamanna R, Luthra R, Singh R, Abraham R, Harmon MA, Mishra B, Hai S, Ho MN, Medeiros L, Patel KP. Clinical Validation of Single Nucleotide Polymorphism Array-Based Comparative Genomic Hybridization in Acute Myeloid Leukemia. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):724-724, 2014. e-Pub 2014.
61. Alayed K, Patel KP, Konoplev SN, Singh R, Routbort MJ, Reddy N, Pemmaraju N, Zhang LP, Alshaikh A, Aladily T, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 Mutations, Myelodysplastic Features, and a Distinct lmmunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 14(3):S128-S128, 2014. e-Pub 2014.
62. Alayed K, Patel KP, Konoplev SN, Singh R, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Al Shaikh A, Aladily T, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 Mutations, Myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 14(Suppl. 3):S128-S128, 2014. e-Pub 2014. PMID: 23940084.
63. Llewellyn TL, Sharma NM, Zheng H, Patel KP. Effects of exercise training on SFO-mediated sympathoexcitation during chronic heart failure. Am J Physiol Heart Circ Physiol 306(1):H121-31, 2014. e-Pub 2014. PMID: 24163080.
64. Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol 41(1):51-7, 2014. e-Pub 2014. PMID: 24151865.
65. Portier BP, Patel KP, Singh R, Routbort M, Handal B, Barkoh BA, Reddy N, Lazar A, Davies M, Medeiros LJ, Aldape K, Luthra R. Next Generation Sequencing of a Large Cohort of Solid Tumors Reveals IDH1 Mutations Present in Melanoma at a Higher Frequency Than Expected. Modern Pathology 26(Suppl. 2):119A-119A, 2013. e-Pub 2013.
66. Wang XI, Patel K, Lin P, Zuo Z, Bueso-Ramos CE, Luthra R, Medeiros JL, Yin CC. Clinicopathologic and Molecular Genetic Features of De Novo Myeloid Sarcoma. Modern Pathology 26(Suppl. 2):365A-365A, 2013. e-Pub 2013.
67. Portier BP, Luthra R, Singh R, Routbort M, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor Based Multi-Gene Next Generation Sequencing. MODERN PATHOLOGY 26(Suppl. 2):499A-520A, 2013. e-Pub 2013.
68. Patel KP, Singh R, Reddy N, Routbort M, Aldape K, Medeiros L, Sargent R, Neelapu SS. Comparison of Next Generation Sequencing Platforms for Multi-Gene. Journal of Molecular Diagnostics 14(6):660-660, 2012. e-Pub 2012.
69. Samaniego F, Wise JF, Tao RH, Zhu HF, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood 120(21), 2012. e-Pub 2012.
70. Patel KP, Luthra MG, Schlette EJ, Wierda W, Keating MJ, Medeiros LJ. Characterization of 6q Deletions in Chronic Lymphocytic Leukemia (CLL). Journal of Molecular Diagnostics 14(6):666-667, 2012. e-Pub 2012.
71. Reddy NG, Singh R, Patel KP, Grant F, Rahimi H, Harmon MA, Handal B, Barkoh BA, Routbort M, Aldape KD, Medeiros LJ, Luthra R. Does Formalin-Fixation and Paraffin-Embedding Affect Genotyping by Next Generation Sequencing?. Journal of Molecular Diagnostics 14(6):738-738, 2012. e-Pub 2012.
72. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KA, Luthra R. Clinical Validation of a Next Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-related Genes. Association of Molecular Pathology Annual Meeting, 2012. e-Pub 2012.
73. Jain P, Kantarjian HM, Faderl S, Patel KP, Garcia Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Luthra R, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. Blood 120(21), 2012. e-Pub 2012.
74. Routbort M, Handal B, Patel KP, Singh R, Aldape K, Reddy N, Barkoh B, Riben M, Medeiros JL, Luthra L. OncoSeek - A Versatile Annotation and Reporting System for Next Generation Sequencing-Based Clinical Mutation Analysis of Cancer Specimens. Journal of Molecular Diagnostics 14(6):747-747, 2012. e-Pub 2012.
75. Kanagal-Shamanna R, Singh RR, Routbort MJ, Aldape KD, Handal B, Rahimi H, Reddy NG, Barkoh BA, Mishra B, Paladugu AV, Manekia J, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Application of Next-Generation Sequencing in Using Fine Needle Aspiration Smears and Cell Blocks from Solid Tumors. Journal of Molecular Diagnostics 14(6):705, 2012. e-Pub 2012.
76. Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju N, Daver N, Konopleva M, Faderl S, Garcia Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors). Blood 120(21), 2012. e-Pub 2012.
77. Lu G, Patel KP, Miranda RN, Medeiros LJ, Chen TJ, Mishra BM, Abraham R, Muddasani R, Luthra R. Genomic analysis by array comparative genomic hybridization of primary myelofibrosis with isolated del(13q). Journal of Molecular Diagnostics 14(6):658-658, 2012. e-Pub 2012.
78. Deqin M, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med 136(5):510-6, 2012. e-Pub 2012. PMID: 22540299.
79. Patel KP, Khokhar FA, Muzzafar T, You MJ, Ravandi F, Bueso-Ramos C, Medeiros LJ. Acute Myeloid Leukemia with Minimal Differentiation: TdT Expression Is Associated with Better Overall Survival Following Stem Cell Transplantation. Modern Pathology 92(1), 2012. e-Pub 2012.
80. Verma S, Greaves WO, Barkoh B, Patel KP, Manekia JH, Patel R, Medeiros LJ, Luthra R. Comparison of High-Throughput Molecular Profiling Platforms for Rapid Mutational Analysis of Myeloid Neoplasms. Modern Pathology 92(1), 2012. e-Pub 2012.
81. Greaves WO, Verma S, Patel KP, Singh R, Reddy NG, Giffard R, Hai S, Yao H, Shen L, Medeiros LJ, Luthra R. A Novel Nanofluidics-Based Single-Platform Molecular Testing Approach for Chronic Myelogenous Leukemia (CML). Modern Pathology 25(2), 2012. e-Pub 2012.
82. Greaves WO, Verma S, Bisrat T, Rahimi H, Paladugu A, Yao H, Patel KP, Luthra R, Medeiros LJ, Verstovsek S, Bueso-Ramos CE. TP53 Mutation Is Rare in Primary Myelofibrosis by High Resolution Melting Curve Analysis and Sanger Sequencing. Modern Pathology 92(1), 2012. e-Pub 2012.
83. Greaves WO, Verma S, Patel KP, Singh R, Reddy NG, Giffard R, Hai S, Yao H, Shen L, Medeiros LJ, Luthra R. A Novel Nanofluidics-Based Single-Platform Molecular Testing Approach for Chronic Myelogenous Leukemia (CML). Modern Pathology 92(1), 2012. e-Pub 2012.
84. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros JL, Luthra R. Detection of High-Frequency and Novel DNMT3A Mutations in Acute Myeloid Leukemia by High Resolution Melting Curve Analysis. Modern Pathology 92(1), 2012. e-Pub 2012.
85. Rahimi H, Singh R, Bartley AN, Patel KP, Barkoh BA, Manekia J, Luthra R. Identification of Rare Mutations in Cancers While Screening for High Frequency Mutations Using Sequenom® MassARRAY System. Journal of Molecular Diagnostics 13(6):766, 2011. e-Pub 2011.
86. Kanagal-Shamanna R, Paladugu A, Barkoh B, Rahimi H, Chen SS, Sargent RL, Medeiros L, Luthra R, Patel KP. Validation of High Resolution Melting Curve Analysis (HRMA) Using Light Cycler 480 for Screening of TP53 Mutations in Human Malignancies. Journal of Molecular Diagnostics 13(6):783-784, 2011. e-Pub 2011.
87. Bartley AN, Luthra R, Yao H, Zuo Z, Medeiros J, Patel KP. Distinct Molecular Characteristics of FLT3 Mutations Involving Multiple. Journal of Molecular Diagnostics 13(6):726, 2011. e-Pub 2011.
88. Greaves WO, Patel KP, Reddy N, Rodriguez S, Hai S, Mishra B, Barkoh BA, Chen SS, Medeiros LJ, Luthra R. A Novel Nanofluidics-Based Approach for Simultaneous and Quantitative Detection of Multiple Recurrent Translocations in Hematologic Malignancies. Journal of Molecular Diagnostics 13(6):734-735, 2011. e-Pub 2011.
89. Ma D, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic Deletions of the PolyA Tract in the 3'-UTR of EGFR are Common in Microsatellite Instability-High Endometrial and Colorectal Carcinomas. Journal of Molecular Diagnostics 13(6):766-767, 2011. e-Pub 2011.
90. Barkoh BA, Patel R, Manekia J, Bartley AN, Zuo Z, Patel K, Luthra R. Comparison of SNaPshot® Fluorescent Capillary Electrophoresis and Sequenom® MassARRAY Based Platforms for Multiplex Solid Tumor Mutation Screening. Journal of Molecular Diagnostics 13(6):775, 2011. e-Pub 2011.
91. Barkoh BA, Do D, Hai S, Yin C, Chen S, Sargent R, Medeiros L, Luthra R, Patel KP. High Resolution Melting Analysis as an Upfront Cost Effective Screening Method for Detection of KIT Exon 17 Mutations in Acute Myeloid Leukemia in the Clinical Laboratory. Journal of Molecular Diagnostics 13(6):732-733, 2011. e-Pub 2011.
92. Reddy NG, Singh R, Paladugu AV, Rahimi H, Patel KP, Luthra R. High Resolution Melt Analysis (HRMA), a Sensitive Screening Method to Detect Exonic Mutations in Phosphatase and Tensin Homologue (PTEN) Gene in Cancers. Journal of Molecular Diagnostics 13(6):766, 2011. e-Pub 2011.
93. Ma D, Chen Z, Cheng H, Djordjevic B, Patel KP, Luthra MG, Barkoh BA, Xie SS, Ma S, Chen G, Medeiros J, Broaddus R, Luthra R. Increased Expression of MicroRNA-210 in Microsatellite Instability High Endometrial Carcinoma and Its Potential Role in DNA Damage Repair. Modern Pathology 24(1890 Suppl. 1):444A-444A, 2011. e-Pub 2011.
94. Ma D, Luthra R, Chen SS, Yin CC, Sargent RL, Patel KP, Medeiros J, Zuo Z. RAS Mutational Analysis in 9334 Solid and Hematopoietic Malignancies. Modern Pathology 24(1677 Suppl. 1):394A-394A, 2011. e-Pub 2011.
95. Greaves WO, Patel KP, Barkoh BA, Mishra BM, Li S, Hui Y, Medeiros LJ, Luthra R. microRNA Profiling in Blastoid Mantle Cell Lymphoma. Modern Pathology 24(1270 Suppl. 1):299A-299A, 2011. e-Pub 2011.
96. Patel KP, Barkoh BA, Chen Z, Ma D, Medeiros LJ, Luthra R. Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia: An Analgorithmic Approach Using High Resolution Melting Curve Analysis. Modern Pathology 24(1928 Suppl. 1):453A-453A, 2011. e-Pub 2011.
97. Ravandi F, Patel KP, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau SM, Garcia-Manero G, Cortes JE, Kantarjian H. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Blood 116(21):1115-1116, 2010. e-Pub 2010.
98. Manekia JH, Patel KP, Barkoh BA, Ma D, Luthra R. Validation of a Leukemia Tumor Mutation Panel by Sequenom MassArray System. Journal of Molecular Diagnostics 12(6):866-866, 2010. e-Pub 2010.
99. Ma D, Djordjevic B, Patel KP, Ao X, Barkoh B, Chen Z, Broaddus R, Luthra R. Assessment of High Resolution Melting Analysis and Immunohistochemical Staining for the Detection of PTEN Mutations. Journal of Molecular Diagnostics 12(6):905-905, 2010. e-Pub 2010.
100. Padula A, Patel KP, Abraham R, Luthra R, Chen SS. PicoPure DNA Extraction A Simple and Efficient Method of DNA Extraction from Formalin Fixed Paraffin Embedded Tissue for Clinical Diagnostic Applications. Journal of Molecular Diagnostics 12(6):913-914, 2010. e-Pub 2010.
101. Barkoh BA, Ma D, Patel KP, Manekia JH, Luthra R. Design and Evaluation of a Solid Tumor Mutation Panel by Sequenom MassARRAY System. Journal of Molecular Diagnostics 12(6):906-906, 2010. e-Pub 2010.
102. Patel KP, Luthra R, Abraham R, Chen SS. Incorporation of Laser Capture Microdissection into Clinical Molecular Testing Workflow. Journal of Molecular Diagnostics 12(6):919-919, 2010. e-Pub 2010.
103. Bartley AN, Patel KP, Barkoh BA, Mishra B, Yao H, Rashid A, Luthra R, Hamilton SR. MicroRNA Expression during the Colorectal Adenoma-Adenocarcinoma Sequence. Modern Pathology 23(Suppl. 1):136A-136A, 2010. e-Pub 2010.
104. Patel KP, Ma D, Barkoh BA, Yao H, Sargent R, Drakos E, Medeiros LJ, Luthra R. MicroRNA Profiling of Anaplastic Large Cell Lymphoma. Modern Pathology 23(1410 Suppl. 1):315A-316A, 2010. e-Pub 2010.
105. Patel KP, Ravandi F, Ma D, Barkoh BA, Paladugu A, Mishra BM, Kantarjian H, Medeiros LJ, Luthra R. The Study of Novel IDH1(R132) Mutations in Acute Myeloid Leukemias. Modern Pathology 23(1409 Suppl. 1):315A-315A, 2010. e-Pub 2010.
106. Patel K, Ravandi F, Ma DQ, Yao H, Abraham R, Barkoh B, Pierce S, Kantarjian H, Luthra R. Detection of Cytogenetic Abnormalities Associated with Outcome Differences in Acute Myeloid Leukemia Using Array-Based Comparative Genomic Hybridization (aCGR) Analysis. Blood 114(22):653-653, 2009. e-Pub 2009.
107. Patel KP, Pan Q, Maitta RW, Du J, Ratech H. Comparison of Multiplex Versus Non-Multiplex Primer Sets for the Detection of T-Cell Receptor-gamma Gene Rearrangement. Modern Pathology 22(1747 Suppl. 1):386A-386A, 2009. e-Pub 2009.
108. Patel KP, Ramesh KH, Conte R, Wei D, Ratech H, Cannizzaro L. Utility of Disease-Specific FISH Panels in the Diagnosis of Hematologic Malignancies. Modern Pathology 22(1269 Suppl. 1):280A-280A, 2009. e-Pub 2009.
109. Patel KP, Ouansafi I, Robbins R, DeCostanzo D, Bhuiya T. Telepathology as a continuing medical education tool: Experience at a multi-hospital health system. Modern Pathology 20(1630 Suppl. 2):354A-354A, 2007. e-Pub 2007.
110. Patel K, Macias A, Wang Y, Sugrue C, Wasserman P. Lessons learned from reflex HPV testing in ASCUS pap smears. Cancer Cytopathology 108(5 Suppl. S):369-370, 2006. e-Pub 2006.
111. Wang Y, Patel K, Sugrue C, Wasserman P. Low-grade squamous intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion (LGSIL-H): Do we need another category in Bethesda System?. Cancer Cytopathology 108(5 Suppl. S):370-370, 2006. e-Pub 2006.
112. Lisovsky M, Patel K, Cymes K, Bhuiya T, Morgenstern N. Anal gland carcinoma: Immunohistochemical characterization. Modern Pathology 19(284 Suppl. 3):64-64, 2006. e-Pub 2006.
113. Ost MC, Patel KP, Rastinehad AR, Chu PY, Anderson AE, Richstone L, Smith AD, Lee BR. Pneumoperitoneum with Co2 inhibits macrophage TNF-Alpha secretion: An etiology for TCC port site metastasis and prophylactic irrigation strategies to decrease oncological risk. Journal of Endourology 20(Suppl. 1):A69-A69, 2006. e-Pub 2006.
114. Patel KP, Esposito M, Heller K, Bhuiya TA. Immunohistochemical analysis of Hurthle cell neoplasms of the thyroid: A hierarchical clustering approach. Modern Pathology 19(433 Suppl. 1):96A-96A, 2006. e-Pub 2006.
115. Chen Y, Patel KP, Alexis C, Ragnath M, Kahn LB, Bhuiya TA. A practical multi-step approach to reduce errors in surgical pathology specimen handling and processing. Modern Pathology 19(1495 Suppl. 1):320A-320A, 2006. e-Pub 2006.
116. Patel KP, Harding P, Glass WF. Changes in actin polymerization regulate plasminogen activator inhibitor type-1 (PAI-1) expression in human mesangial cells. FASEB Journal 18(5 Suppl. S):A942-A942, 2004. e-Pub 2004.
117. Patel KP, Harding P, Glass WF. Regulation of alpha-SMA expression and hypertrophy by changes in actin polymerization in mesangial cells. Journal of the American Society of Nephrology 13(Suppl. S):94A-94A, 2002. e-Pub 2002.

Book Chapters

1. Salim AA, Patel KP. Molecular Platforms for Melanoma Mutation Analysis. In: Molecular Platforms for Melanoma Mutation Analysis, 193, 2018.
2. Mehrotra M, Patel KP. High-Resolution Melt Curve Analysis in Cancer Mutation Screen. In: Methods Mol Biol, 63-9, 2016.
3. Patel KP, Galbincea J Luthra R. Mutational Analysis in Cancer. In: Modern Clinical Molecular Techniques, 2012.
4. Patel KP. Lymphoproliferative Disorders Associated with Primary Immune Disorders. In: Diagnostic Pathology: Pediatric Neoplasms, 2012.
5. Patel K. Lymphoproliferative Disorders Associated with Primary Immune Disorders. In: Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas, 2011.

Books (edited and written)

1. Luthra R, Patel KP, Singh RR. Clinical Applications of PCR. Humana Press, 2016.

Letters to the Editor

1. Dimopoulos YP, Wang W, Wang SA, Loghavi S, DiNardo CD, Gerstein Y, Hu S, Tang Z, Ilagan CJL, Thakral B, El Hussein S, Xu J, Li S, Lin P, Patel KP, Ok CY, Medeiros LJ, Fang H. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol 99: 2416-2419, 2024.
2. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma 65: 1511-1515, 2024.
3. Abuasab, T, Borthakur, G, Kanagal Shamanna, R, Masarova, L, Patel, KP, Takahashi, K, Bose, P, Villarreal, J, Pierce, S, Kadia, TM, Garcia-Manero, G, Short, NJ, DiNardo, C, Daver, N, Ravandi-Kashani, F, Kantarjian, H, Verstovsek, S, Yilmaz, M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms. American journal of hematology 99: 1434-1436, 2024.
4. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Ramos Perez JM, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood, 2018.
5. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 10: 2584-2587, 2017.
6. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). American Journal of Hematology 92: E3-E4, 2017.
7. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 30: 980-4, 2016.